SGLT2 inhibitors: providing cardiovascular protection in type 2 diabetes? [PDF]
Wilding, John
core +1 more source
The use of SGLT2 inhibitors in older people: What is important? [PDF]
Armentaro G +12 more
europepmc +1 more source
Response to the Letter to the Editor Entitled "SGLT2 Inhibitors in ADPKD: Time to Integrate Cardiovascular Outcomes". [PDF]
Uchiyama K.
europepmc +1 more source
SGLT2 inhibitors in CKD: are they really effective in all patients? [PDF]
Romagnani P.
europepmc +1 more source
Luseogliflozin reduces epicardial fat accumulation in patients with type 2 diabetes: a pilot study [PDF]
core +1 more source
SGLT2 Inhibitors and Long-Term Outcomes After AKI. [PDF]
Wannakittirat A +9 more
europepmc +1 more source
Preventing atrial fibrillation with SGLT2 inhibitors: time, sex, and substrate. [PDF]
Karakasis P, Antoniadis AP, Fragakis N.
europepmc +1 more source
Az antidiabetikumok kardiovaszkuláris szerepe a véletlen besorolásos vizsgálatokban és az újabb ajánlások világában = Cardiovascular role of novel antidiabetics in randomized controlled trials and newer recommendations [PDF]
Bajnok, László
core +1 more source
Efficacy of SGLT2 Inhibitors on Clinical Outcomes After Transcatheter Aortic Valve Replacement: A Systematic Review and Meta-Analysis. [PDF]
Daniyal SM +14 more
europepmc +1 more source
SGLT2 Inhibitors In Older Adults With Cardiovascular Disease: A Systematic Review And Meta‐Analysis [PDF]
Minami K +7 more
europepmc +2 more sources

